With $18M In Series B Funds, Edimer To Test Protein-Replacement Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Building on Swiss research, the biotech hopes to develop the first therapy for X-linked hypohidrotic ectodermal dysplasia, a genetic mutation that can impact development of teeth, hair and skin. After Phase I testing in adults, Edimer now plans to test EDI200 in six to 10 infants in Phase II.
You may also be interested in...
Edimer Pharmaceuticals Inc.
Edimer Pharmaceuticals Inc. is poised to begin the first human trials of a protein-replacement therapy for XLHED, a disorder that impacts the development of teeth, hair and skin. Although the start-up is planning to test its therapy first in adults, Edimer's ultimate goal is to permanently correct the disorder by treating developing fetuses in utero. The company's compound is designed to cross the placental barrier, so that it can bind an endogenous receptor and trigger normal fetal development with just a single treatment.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: